The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The ATOM trial: A multicenter, randomized phase II study of modified FOLFOX6 plus bevacizumab and modified FOLFOX6 plus cetuximab for colorectal cancer with liver-limited metastases.
 
Yasunori Emi
Honoraria - Chugai Pharma; Merck Serono; Taiho Pharmaceutical; Yakult Honsha
 
Kei Muro
Speakers' Bureau - Taiho Pharmaceutical
 
Takeharu Yamanaka
No Relationships to Disclose
 
Yu Katayose
No Relationships to Disclose
 
Hiroyuki Uetake
No Relationships to Disclose
 
Kenichi Sugihara
No Relationships to Disclose
 
Yoshihiro Kakeji
Honoraria - Chugai Pharma; Taiho Pharmaceutical
 
Michiaki Unno
Honoraria - Astellas Pharma; Chugai Pharma; Eisai; Janssen; Johnson & Johnson; Lilly; Novartis; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Chugai Pharma (Inst); Janssen (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Ichinosuke Hyodo
Research Funding - Chugai Pharma; Daiichi Sankyo; Taiho Pharmaceutical; Yakult Honsha
 
Naohiro Tomita
No Relationships to Disclose
 
Yoshihiko Maehara
Research Funding - Bristol-Myers Squibb Japan; Chugai Pharma; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha